1. Testing positive for HIV, HbsAg and HCV infection. <br/ >2. Females who are currently pregnant or breastfeeding. <br/ >3. Allergy or other contraindication to one of the investigational products. <br/ >4. Has received Eflornithine within the last 10 days. <br/ >5. Has received anti-viral, anti-malarial or anti-bacterial within the last 14 <br/ >days. <br/ >6. Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) <br/ > > 5 X upper limit of normal (ULN). <br/ >7. QTc interval â?¥ 500ms. <br/ >8. Recent Myocardial Infarction (within last 6 months). <br/ >9. Known case of (K/C/O) Congestive heart failure. <br/ >10. K/C/O Chronic Kidney Disease. <br/ >11. K/C/O active Tuberculosis. <br/ >12. History of drug or alcohol dependence in the past 6 months. <br/ >13. In the opinion of the clinical team, progression to death is imminent and <br/ >inevitable within the next 24 hours, irrespective of the provision of <br/ >treatments. <br/ >14. Anticipated transfer to another hospital which is not a study site within <br/ >72 hours. <br/ >15. K/C/O of epilepsy.

1. Testing positive for HIV, HbsAg and HCV infection. <br/ >2. Females who are currently pregnant or breastfeeding. <br/ >3. Allergy or other contraindication to one of the investigational products. <br/ >4. Has received Eflornithine within the last 10 days. <br/ >5. Has received anti-viral, anti-malarial or anti-bacterial within the last 14 <br/ >days. <br/ >6. Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) <br/ > > 5 X upper limit of normal (ULN). <br/ >7. QTc interval â?¥ 500ms. <br/ >8. Recent Myocardial Infarction (within last 6 months). <br/ >9. Known case of (K/C/O) Congestive heart failure. <br/ >10. K/C/O Chronic Kidney Disease. <br/ >11. K/C/O active Tuberculosis. <br/ >12. History of drug or alcohol dependence in the past 6 months. <br/ >13. In the opinion of the clinical team, progression to death is imminent and <br/ >inevitable within the next 24 hours, irrespective of the provision of <br/ >treatments. <br/ >14. Anticipated transfer to another hospital which is not a study site within <br/ >72 hours. <br/ >15. K/C/O of epilepsy.

N/A

N/A

1. Testing positive for HIV, HbsAg and HCV infection. <br/ >2. Females who are currently pregnant or breastfeeding. <br/ >3. Allergy or other contraindication to one of the investigational products. <br/ >4. Has received Eflornithine within the last 10 days. <br/ >5. Has received anti-viral, anti-malarial or anti-bacterial within the last 14 <br/ >days. <br/ >6. Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) <br/ > > 5 X upper limit of normal (ULN). <br/ >7. QTc interval â?¥ 500ms. <br/ >8. Recent Myocardial Infarction (within last 6 months). <br/ >9. Known case of (K/C/O) Congestive heart failure. <br/ >10. K/C/O Chronic Kidney Disease. <br/ >11. K/C/O active Tuberculosis. <br/ >12. History of drug or alcohol dependence in the past 6 months. <br/ >13. In the opinion of the clinical team, progression to death is imminent and <br/ >inevitable within the next 24 hours, irrespective of the provision of <br/ >treatments. <br/ >14. Anticipated transfer to another hospital which is not a study site within <br/ >72 hours. <br/ >15. K/C/O of epilepsy.

1. Testing positive for HIV, HbsAg and HCV infection. <br/ >2. Females who are currently pregnant or breastfeeding. <br/ >3. Allergy or other contraindication to one of the investigational products. <br/ >4. Has received Eflornithine within the last 10 days. <br/ >5. Has received anti-viral, anti-malarial or anti-bacterial within the last 14 <br/ >days. <br/ >6. Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) <br/ > > 5 X upper limit of normal (ULN). <br/ >7. QTc interval â?¥ 500ms. <br/ >8. Recent Myocardial Infarction (within last 6 months). <br/ >9. Known case of (K/C/O) Congestive heart failure. <br/ >10. K/C/O Chronic Kidney Disease. <br/ >11. K/C/O active Tuberculosis. <br/ >12. History of drug or alcohol dependence in the past 6 months. <br/ >13. In the opinion of the clinical team, progression to death is imminent and <br/ >inevitable within the next 24 hours, irrespective of the provision of <br/ >treatments. <br/ >14. Anticipated transfer to another hospital which is not a study site within <br/ >72 hours. <br/ >15. K/C/O of epilepsy.